Intravitreous injection: Retrospective study on 2028 injections and their side effects;Injection intravitréenne: Évaluation rétrospective de la technique et des complications d'une série de 2028 injections

Journal Francais d'Ophtalmologie

Volumn 31, Issue 7, 2008, Pages 693-698

  Angulo Bocco, M C ^a,b   Glacet Bernard, A ^a,b   Zourdani, A ^a,b   Coscas, G ^a,b   Soubrane, G ^a,b  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

AMD; Cataract; Diabetic macular edema; Endophtalmitis; Intraocular pressure; Intravitreous injection; Macular edema; Macular hole; Pegaptanib; Ranibizumab; Retinal vein occlusion; Triamcinolone

Indexed keywords

EID: 55049109170     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(08)74383-3     Document Type: Article

References (29)

1. Sakamoto T, Enaida H, Kubota T, Nakahara M, Yamakiri K, Yamashita T, et al. Incidence of acute endophtalmitis after triamcinolone assisted pars plana vitrectomy. Am J Ophtalmol, 2004;138:137-8.
2. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Non infectious endophtalmitis associated with intravitrel triamcinolone injection. Arch Ophthalmol, 2003;121:1279-82.
3. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina, 2003;23:689-91.
4. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, et al. Acute endophtalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol, 200;136:791-6.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 2004;35:2805-16.
6. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006;355:1419-31.
7. Baudouin C, Fredj-Reygrobellet D, Ettaiche M, Barritault D, Gastaud P, Lapalus P. Induction of experimental proliferative vitreoretinopathy in the rabbit eye by intravitreal injections of fibroblast growth factor. Eye Toxic Res, 1992;9:505-11.
8. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, et al. Evolving guidelines for intravitreous injections. Retina, 2004;24:S3-19.
9. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol, 2006;141:579-80.
10. Maia M, Farah ME, Belfort RN, Penha FM, Lima Filho AA, Aggio FB, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol, 2007;91:122-4.
11. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol, 2006;141:629-37
12. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol, 2006;90:999-1003.
13. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Opthalmol, 2003;87:24-7.
14. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol, 2004;137:560-2.
15. Jonas JB, Spandau UH, Kamppeter BA, Vossmerbaeumer U, Harder B, Sauder G. Repeated Intravitreal High-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology, 2006;113:800-4.
16. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM. Intravitreal triamcinolone-Induced elevated intraocular pressure in associated with the development of posterior subcapsular cataract. Ophthalmology, 2005;112:139-43.
17. Detry-Morel M, Escarmelle A, Hermans I. Refractory ocular hypertension secondary to intravitreal injection of triamcinolone acetonide. Bull Soc Belge Ophtalmol, 2004;292:45-51.
18. Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Iyer MN, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology, 2006;113:1174-8.
19. Batioǧlu F, Ozmert E, Parmak N, Celik S. Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema. Int Ophthalmol, 2007;27:299-306.
20. Nkeme J, Glacet-Bernard A, Gnikpingo K, Zourdani A, Mimoun G, Mahiddine H et al. [Surgical treatment of persistent macular edema in retinal vein occlusion]. J Fr Ophtalmol, 2006;29:808-14.
21. Hariprasad SM, Shah GK, Blinder KJ. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol, 2006;141:200-1.
22. Islam MS, Vernon SA, Negi A. Intravitreal triamcinolone will cause posterior subcapsular cataract in most eyes with diabetic maculopathy within 2 years. Eye, 2007;21:321-3.
23. Jonas JB, Degenring R, Vossmerbauemer U, Kamppeter B. Frequency of cataract surgery after intravitreal injection of high- dosage Triamcinolone acetonide. Eur J Ophthalmol, 2005;15:462-4.
24. Glacet Bernard A, Voigt M, Coscas G, Soubrane G. Full-Thickness macular hole following intravitreal injection of triamcinolone acetonide in central retinal vein occlusion. Retina, 2008;(under press).
25. Smiddy WE, Flynn HW Jr. Pathogenesis of macular holes and therapeutic implications. Am J Ophthalmol 2004;37:525-37.
26. Jonas JB, Kreissig I, Degenring RF. Retinal complications of intravitreal injections of triamcinolone acetonide (letter). Graefes Arch Clin Exp Ophthalmol 2004;242:184-5.
27. Jaissle GB, Szurman P, Bartz Schmidt KU. Recommendation for the implementation of intravitreal injections-statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd, 2005;222:390-5.
28. Korobelnik JF, Cochereau I, Cohen SY, Coscas G, Creuzot-Garcher C, Devin F et al. Description des pratiques pour la réalisation des injections intravitréennes. J Fr Ophtalmol, 2006;29:82-6.
29. Glacet-Bernard A. Injection intravitréenne: technique et recommandations. In: Soubrane G. Les DMLAs. Rapport de la société française d'ophtalmologie. Paris, Masson éditeur; 2007. p. 534-6.